French clinical-stage biotech developing a nanoparticle injected into tumors to enhance the effect of radiotherapy.
French clinical-stage biotech developing a nanoparticle injected into tumors to enhance the effect of radiotherapy.
Has no commercial revenue to speak of: income comes from licence payments, notably the 2019 deal with Janssen, Johnson & Johnson's pharmaceutical arm, which gave it a partner outside the US. Hensify has a European CE mark for soft-tissue sarcoma but is mostly a development-stage product.
In one line: A radiotherapy-enhancement biotech, unlike any single US analogue.
Moat: narrow (IP / patents, regulatory licence). Patented nanoparticle technology with regulatory approval in some markets, but unproven at commercial scale.
Headquarters: Paris, France · Founded: 2003 · Employees: 97
Size Nanobiotix (NANO.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.35B, the 121st largest of 206 France companies the cockpit tracks. Shares closed at €24.08 on 18 Nov 2026.
Performance Over six months the shares fell 31.9%, against -14.7% for the median peer and -2.1% for the France market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue fell 76.9% over the last twelve months (peer median +12.4%); the operating margin is -392.0% (peer median 10.9%).
Valuation It trades at 146.3× enterprise value to sales against a peer median of 4.0× (3rd most expensive of 18).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €8.36M | €29.6M | -€11.6M | €30.1M | €0 |
| Revenue growth | — | — | -139% | — | — |
| Gross profit | n/a | n/a | n/a | n/a | -€1.50M |
| EBITDA | -€31.2M | -€12.2M | -€71.1M | -€28.9M | -€49.0M |
| Net income | -€52.9M | -€24.0M | -€68.1M | -€39.7M | -€57.0M |
| Free cash flow | -€40.2M | -€35.5M | -€21.4M | -€19.8M | -€38.1M |
| Capital expenditure | €1.01M | €546,000 | €848,000 | €337,000 | €93,000 |
| Total debt | n/a | €95.3M | €50.9M | €50.6M | €53.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Nanobiotix NANO.PA | $1.35B | -32% | -77% | -392% | 146.3× | n/a |
| Siemens Healthineers SHL.DE | $53.7B | +27% | +1% | 14% | 2.6× | 9.6% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 3.5× | 5.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NANO.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.6% | -2.3% | 3rd highest of 20 |
| 6-month return | -31.9% | -14.7% | 4th lowest of 20 |
| Distance from 52-week high | -49.5% | -40.0% | 6th lowest of 20 |
| Revenue growth (TTM) | -76.9% | +12.4% | 2nd lowest of 18 |
| Operating margin | -392.0% | 10.9% | 3rd lowest of 18 |
| EV / Sales | 146.3× | 4.0× | 3rd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | 146.3× | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 3.0× | 3.9% | +22.8% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | 125.0× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | 4.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | 3.0× | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 9.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 4.0× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 2.2× | -17.2% | +3.9% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 2.1× | -9.6% | +4.6% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | 17.0× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 0.8× | -18.1% | +7.0% |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 3.8× | 31.0% | +16.6% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | 85,633.6× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | 216.0× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |